公开(公告)号：US20220362205A1

公开(公告)日：2022-11-17

申请号：US17873800

申请日：2022-07-26

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K47/64 ,  A61K9/08 ,  A61K47/42

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

公开(公告)号：US11419842B2

公开(公告)日：2022-08-23

申请号：US16345615

申请日：2017-10-27

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K47/64 ,  A61K9/08 ,  A61K47/42

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

公开(公告)号：US11413265B2

公开(公告)日：2022-08-16

申请号：US16982252

申请日：2019-04-19

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/335 ,  A61P35/00 ,  A61K31/337 ,  A61K31/198 ,  A61K38/38 ,  A61K9/08

Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.

公开(公告)号：US20200345681A1

公开(公告)日：2020-11-05

申请号：US16886415

申请日：2020-05-28

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K9/00 ,  A61K9/19 ,  A61K38/38 ,  A61P35/00 ,  C07D305/14 ,  A61K47/42 ,  A61K9/08

Abstract: This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.

公开(公告)号：US20250017892A1

公开(公告)日：2025-01-16

申请号：US18899360

申请日：2024-09-27

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K9/08 ,  A61K38/38 ,  A61K47/42 ,  A61K47/64

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

公开(公告)号：US20220226444A1

公开(公告)日：2022-07-21

申请号：US17713872

申请日：2022-04-05

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K38/38 ,  A61K31/5377 ,  A61K31/675 ,  A61K9/08 ,  A61K47/42 ,  A61K9/19 ,  A61K9/00

Abstract: This document relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, and human serum albumin, wherein the fosaprepitant, or a pharmaceutically acceptable salt thereof, and the human serum albumin in the composition have a ratio by weight from about 1:0.1 to about 1:500. This document also relates to a composition comprising aprepitant and human serum albumin, wherein the aprepitant and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:1000. This document also relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, aprepitant and human serum albumin.

公开(公告)号：US20190142748A1

公开(公告)日：2019-05-16

申请号：US16304423

申请日：2017-05-25

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K9/08 ,  A61K38/38 ,  A61K31/196 ,  A61K47/24 ,  A61K47/12 ,  A61K9/19

Abstract: This document relates to an aqueous composition comprising chlorambucil and human serum albumin, wherein the chlorambucil and the human serum albumin in the aqueous composition have a ratio by weight from about 1:10 to about 1:2000, wherein the aqueous composition comprises at least one water-miscible organic solvent. This document also relates to a solid composition comprising chlorambucil and human serum albumin. This document also relates to a liquid pharmaceutical composition comprising the solid composition comprising the chlorambucil and the human serum albumin, and a pharmaceutically acceptable carrier.

公开(公告)号：US09962452B2

公开(公告)日：2018-05-08

申请号：US14765773

申请日：2014-01-31

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K47/48 ,  A61K31/4745

CPC classification number: A61K47/643 ,  A61K31/337 ,  A61K31/4745

Abstract: The present invention provides novel, non-covalently bound complexes of serum albumin and analogs of poorly soluble drugs, such as camptothecin. The novel complexes are significantly more water-soluble than the camptothecin analogs and are useful as prodrug forms of the camptothecin analogs for the treatment of mammalian cell proliferative diseases, such as cancer.

公开(公告)号：US20240189272A1

公开(公告)日：2024-06-13

申请号：US18387327

申请日：2023-11-06

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K9/08 ,  A61K9/14 ,  A61K38/38 ,  A61K47/12

CPC classification number: A61K31/337 ,  A61K9/08 ,  A61K9/14 ,  A61K38/385 ,  A61K47/12

Abstract: This document relates to a composition comprising docetaxel, proteins comprising a human serum albumin, and sodium caprylate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:70 to about 1:300, and wherein the composition does not contain sodium N-acetyltryptophanate. This document also relates to a composition consisting essentially of docetaxel, proteins comprising a human serum albumin, and sodium caprylate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:70 to about 1:300, and wherein the composition does not contain sodium N-acetyltryptophanate. This document also relates to a composition comprising docetaxel, proteins comprising a human serum albumin, and sodium N-acetyltryptophanate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:80 to less than 1:150.

公开(公告)号：US20210052540A1

公开(公告)日：2021-02-25

申请号：US16982252

申请日：2019-04-19

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K31/198 ,  A61K38/38

Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.